NCT00675870View on ClinicalTrials.gov

Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia

PHASE2UnknownINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

April 30, 2010

Conditions
Acute Promyelocytic Leukemia
Interventions
DRUG

NRX 195183 Soft Gelatin Capsule

Daily oral NRX 195183 administration for 90 days to assess CR rate. Patients with CR may continue maintenance therapy after a 2-week drug holiday. Maintenance therapy will consist of two 3-month daily oral NRX 195183 administration separated by a 2-week drug holiday.

Trial Locations (1)

90403

RECRUITING

Sarcoma Oncology Center, Santa Monica

Sponsors
All Listed Sponsors
lead

NuRx Pharmaceuticals, Inc.

INDUSTRY

NCT00675870 - Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia | Biotech Hunter | Biotech Hunter